Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum

BACKGROUND: To evaluate the activity and safety of everolimus and identify potential biomarkers for efficacy of everolimus in patients with advanced gastric cancer (AGC), who failed both fluoropyrimidine and platinum. METHODS: Fifty-four patients received everolimus (10 mg day(−1)). The primary obje...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, D H, Ryu, M-H, Park, Y S, Lee, H J, Lee, C, Ryoo, B-Y, Lee, J-L, Chang, H-M, Kim, T W, Kang, Y-K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304416/
https://www.ncbi.nlm.nih.gov/pubmed/22343617
http://dx.doi.org/10.1038/bjc.2012.47

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304416/
https://www.ncbi.nlm.nih.gov/pubmed/22343617
http://dx.doi.org/10.1038/bjc.2012.47

Ejemplares similares